Selling, General, and Administrative Costs: Mesoblast Limited vs Viridian Therapeutics, Inc.

Biotech Giants' SG&A Costs: A Decade of Change

__timestampMesoblast LimitedViridian Therapeutics, Inc.
Wednesday, January 1, 2014541700007751000
Thursday, January 1, 20156537800010251000
Friday, January 1, 2016522630009575000
Sunday, January 1, 20173507200010912000
Monday, January 1, 20182741500011049000
Tuesday, January 1, 20193698300011646000
Wednesday, January 1, 20205091800013265000
Friday, January 1, 20216358600025805000
Saturday, January 1, 20225796700035182000
Sunday, January 1, 20235310700094999000
Monday, January 1, 202423626000
Loading chart...

Unlocking the unknown

A Tale of Two Biotechs: Mesoblast Limited vs. Viridian Therapeutics, Inc.

In the ever-evolving landscape of biotechnology, understanding financial health is crucial. This chart offers a glimpse into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Mesoblast Limited and Viridian Therapeutics, Inc., from 2014 to 2023.

Mesoblast Limited, an Australian regenerative medicine company, has seen its SG&A expenses fluctuate, peaking in 2015 and 2021. Notably, their expenses in 2023 were approximately 56% lower than their 2015 peak. In contrast, Viridian Therapeutics, Inc., a U.S.-based biotech firm, experienced a dramatic rise in SG&A costs, with a staggering 1,125% increase from 2014 to 2023.

This data highlights the contrasting financial strategies and growth trajectories of these companies, offering valuable insights for investors and industry analysts. Missing data for 2024 suggests ongoing developments worth monitoring.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025